海外の治験の状況「1」での検索結果
251件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 地域
- 登録日
Authorised
- A study of the Safety and Effectiveness of Pegylated Recombinant Factor VIII (BAX 855) in Prevention of Bleeding in Patients with Severe Hemophilia A (a blood clotting disorder) using two different dosing schedules to target different levels of BAX855 in the blood.
- Severe hemophilia A (FVIII 1%) MedDRA version: 20.0 Level: LLT Classification code 10060612 Term: Hemophilia A System Organ Class: 100000011915 ;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
- Australia, Austria, Bulgaria, Czech Republic, France, Germany, Hong Kong, Hungary, Israel, Italy, Malaysia, Poland, Singapore, Spain, Sweden, Taiwan, Turkey, Ukraine, United Kingdom, United States
- 2015-10-12
Authorised
- A clinical study involving previously untreated patients with haemophilia A to look at how safe an experimental replacement factor VIII protein (known as rFVIIIFc) is to take and how well it works to prevent and stop bleeds.
- Hemophilia A MedDRA version: 20.0 Level: LLT Classification code 10053753 Term: Hemophilia A without inhibitors System Organ Class: 100000004850 MedDRA version: 20.0 Level: LLT Classification code 10060612 Term: Hemophilia A System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
- Australia, Brazil, Canada, Denmark, France, Germany, Ireland, Italy, Netherlands, New Zealand, Poland, Spain, Sweden, United Kingdom, United States
- 2014-05-06
Authorised
- Influence of insulin Levemir on endothelial function in type 2 diabetes mellitus. A prospective case-control study. - Levemir on endothelial function
- Patients with known history of type 2 Diabetes Mellitus longer than 6 months, who were treated by diet in combination with oral antidiabetic drugs (OADs) are to be included in the study.
- Austria
- 2007-08-24
Authorised
- Insulin aspart (NovoRapid®, Novo Nordisk) vs. human insulin (Actrapid®, Novo Nordisk) in intravenous treatment of high blood glucose concentrations in the ICU
- Therapy of hyperglycemia by intravenously applied insulin is going to be investigated. Hyperglycemia is very common in hospitalized, critically ill patients, even if they have not previously had diabetes. Studies have established that in-hospital hyperglycemia is associated with higher mortality and morbidity. Therefore, careful monitoring and therapy of hyperglycemia have become standard in the ICU and include treatment with continuous infusion of insulin. br>MedDRA version: 9.1 Level: LLT Classification code 10042216 Term: Stress induced hyperglycemia
- Austria
- 2007-04-18
Authorised
- Not available
- Familial Amyloid Polyneuropathy br>MedDRA version: 20.0 Level: LLT Classification code 10057949 Term: Familial amyloid polyneuropathy System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
- Argentina, Brazil, France, Germany, Italy, New Zealand, Portugal, Spain, United Kingdom, United States
- 2014-05-07
Authorised
- A Non-Interventional Study to Monitor the Survival Status of Patients that Discontinued from ISIS 420915-CS2 or ISIS 420915-CS3
- Familial Amyloid Polyneuropathy br>MedDRA version: 20.0 Level: LLT Classification code 10057949 Term: Familial amyloid polyneuropathy System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
- Argentina, Brazil, France, Germany, Italy, New Zealand, Portugal, Spain, United Kingdom, United States
- 2018-02-19
Authorised
- A clinical trial of a Tailored ImmunoTherapy Approach with Nivolumab in subjects with metastatic or advanced Renal Cell Carcinoma
- subjects with previously untreated (1st line) or pretreated (2nd line), intermediate or high risk, advanced or metastatic renal cell carcinoma MedDRA version: 20.0 Level: LLT Classification code 10038400 Term: Renal carcinoma stage IV System Organ Class: 100000004864 MedDRA version: 20.0 Level: LLT Classification code 10038399 Term: Renal carcinoma stage III System Organ Class: 100000004864 MedDRA version: 20.0 Level: LLT Classification code 10050076 Term: Metastatic renal carcinoma System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Austria, Czech Republic, Germany, Spain
- 2016-06-27
Authorised
- Evaluation of the therapy of Hodgkin’s Lymphoma in Children and Adolescents
- The first line therapy for childhood nodular lymphocyte-predominant Hodgkin’s lymphoma shall be further optimised to avoid over-treatment and decrease long-term complications. MedDRA version: 14.0 Level: HLT Classification code 10020226 Term: Hodgkin's disease lymphocyte predominance type System Organ Class: 10005329 - Blood and lymphatic system disorders ;Therapeutic area: Diseases [C] - Cancer [C04]
- Austria, Czech Republic, Germany, United Kingdom, United States
- 2009-03-10
Authorised
- Phase I/II comparison of efficacy and safety of BBF 1120 and sorafenib in patients with advanced hepatocellular carcinoma
- Histologically or cytologically confirmed hepatocellular carcinoma not amenable to local therapy with adequate renal, hematological and liver paramenters with Child-Pugh score 7 or less, in 1st line systemic therapy. Note for phase II only liver function group I patients with Child Pugh A will be enrolled MedDRA version: 16.1 Level: LLT Classification code 10049010 Term: Carcinoma hepatocellular System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Austria, Germany, Hungary, United Kingdom
- 2009-07-23
Authorised
- PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive/HER2-negative early breast cancer
- To determine whether the addition of palbociclib to adjuvant endocrine therapy will improve outcomes over endocrine therapy alone for HR+/HER2- early breast cancer. MedDRA version: 20.1 Level: LLT Classification code 10070575 Term: Estrogen receptor positive breast cancer System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Austria, Belgium, Canada, Germany, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic of, Mexico, Netherlands, Poland, Portugal, Spain, Sweden, Switzerland, Taiwan, United Kingdom, United States
- 2015-06-11
